Adam Bersani, DPM
Podiatrist · Liverpool, NYNPI 1790282275
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,250 of the $10,338 with a category attached, or 60.5%. Arthrex accounts for 76.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $5,390 and has fallen 73.0% since, to $1,453 in 2025. Among podiatrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 54 payments — averaging $191.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$8K
- Prodigy Surgical Distribution, Inc.$991
- Rock Medical Orthopedics, Inc.$676
- Treace Medical Concepts, Inc.$205
- Organogenesis Inc.$192
- Paratek Pharmaceuticals, Inc.$178
- plus $231 from 3 others
What the payments were for
- Speaking & faculty fees$6,25060%
- Travel & lodging$2,01419%
- Food & beverage$1,39814%
- Education$6767%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 30 | $7,865 |
| Prodigy Surgical Distribution, Inc. | 4 | $991 |
| Rock Medical Orthopedics, Inc. | 1 | $676 |
| Treace Medical Concepts, Inc. | 7 | $205 |
| Organogenesis Inc. | 4 | $192 |
| Paratek Pharmaceuticals, Inc. | 4 | $178 |
| AbbVie | 1 | $115 |
| Aroa Biosurgery Incorporated | 1 | $85 |
| Amgen(2 entities) | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,338 in reported general payments places this provider in the 95th percentile of 862 podiatrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 19 | $374 |
| Gabapentin | 44 | $282 |
| Terbinafine Hcl | 15 | $275 |
| Cephalexin | 21 | $76 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $66 |
| Meloxicam | 28 | $12 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Liverpool
- Christopher BromleyPoughkeepsie$152K
- Scott GawlikBrooklyn$77K
- Waldemar MajdanskiAstoria$71K
- Michael HutzelSeaford$64K
- Donald RubinCorning$53K
- Steven NormanMiddle Village$42K
- Elvis DanneNew York$35K
- Adam CirlincioneGlen Cove$31K
- Jude ViolanteNiagara Falls$30K
- Ammar Al RubaiayNew Hyde Park$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.